---
title: "Bezuclastinib in Gastrointestinal stromal tumor: References"
description: "Reference list for the formulary evidence report on Bezuclastinib in Gastrointestinal stromal tumor. 76 cited documents."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Gastrointestinal stromal tumor: References

<a id="references"></a>

## 5 References

1. [Accessia Health (2022)](https://accessiahealth.org/living-with-gist/)
2. [ANZCTR NCT00075218](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=418&isClinicalTrial=True)
3. [Banerjee et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7522695/)
4. [Bauer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9746771/)
5. [British Sarcoma Group (2024)](https://www.nature.com/articles/s41416-024-02672-0)
6. [Call et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37143339/)
7. [Casali et al. (2022)](https://doi.org/10.1016/j.annonc.2021.09.005)
8. [Centanni et al. (2025)](https://link.springer.com/article/10.1007/s40273-024-01438-z)
9. [Chabot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18372169/)
10. [ChemScene (2025)](https://www.chemscene.com/quality-control.html?q=MSDS%2FMSDS%23USA%23CS%23CS-0376032.pdf)
11. [Cogent Biosciences](https://cogentbio.com/bezuclastinib/)
12. [Cogent Biosciences (2020)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-final-results-plx9486-phase-12)
13. [Cogent Biosciences (2024)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-updated-lead-data-ongoing)
14. [Cogent Biosciences (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-positive-results-bezuclastinib-peak)
15. [Cogent Biosciences AdvSM new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-1)
16. [Cogent Biosciences ASCO poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/06/CogentBio_ASCO-2023-Peak.pdf)
17. [Cogent Biosciences CTOS poster (2023)](https://www.cogentbio.com/wp-content/uploads/2023/11/CogentBio_CTOS-2023-Peak-TiP_final.pdf)
18. [Cogent Biosciences first quarter 2026 financial results (2026)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)
19. [Cogent Biosciences Form 10-K (2023)](https://www.sec.gov/Archives/edgar/data/1622229/000095017023007729/cogt-20221231.htm)
20. [Cogent Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm)
21. [Cogent Biosciences GIST Breakthrough Therapy designation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-breakthrough-therapy-designation)
22. [Cogent Biosciences GIST new drug application acceptance announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0)
23. [Cogent Biosciences GIST new drug application submission announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application-0)
24. [Cogent Biosciences GIST new drug application submission initiation announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-initiate-new-drug-application-nda-submission)
25. [Cogent Biosciences investor overview](https://investors.cogentbio.com/)
26. [Cogent Biosciences PEAK detailed results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-detailed-clinical-data-peak-phase-3)
27. [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/9cb70bb1-3263-4a80-8af9-36b0037418de)
28. [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)
29. [Cogent Biosciences third quarter 2026 financial results (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-12)
30. [Dana-Farber Cancer Institute (2026)](https://www.newswise.com/articles/dana-farber-researchers-to-present-two-plenary-studies-and-additional-late-breaking-cancer-research-at-2026-asco)
31. [Dana-Farber Cancer Institute SARC044 trial page](https://www.dana-farber.org/clinical-trials/24-195)
32. [Dana-Farber Cancer Institute sunitinib continuous daily dosing trial page](https://www.dana-farber.org/clinical-trials/05-177)
33. [Datar and Khanna (2012)](https://jgo.amegroups.org/article/view/605/html)
34. [Demetri et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17046465/)
35. [den Hollander et al. (2022)](https://link.springer.com/article/10.1007/s00520-022-06929-3)
36. [Equinox Group (2026)](https://www.equinox-group.com/our-take-blog//cogents-bezuclastinib-reduces-risk-of-disease-progression-or-death-by-50-in-2l-metastatic-gist-when-combined-with-standard-of-care)
37. [FDA (2018)](https://www.fda.gov/media/71195/download)
38. [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=827121)
39. [Feng et al. (2022)](https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2021.768765/full)
40. [Gebreyohannes et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523507/)
41. [GEIS (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10467260/)
42. [George et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19282169/)
43. [Guarnieri et al. (2022)](https://aacrjournals.org/cancerres/article/82/12_Supplement/147/700903/Abstract-147-Bezuclastinib-is-a-differentiated-KIT)
44. [Guérin et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25422992/)
45. [Haddox et al. (2024)](https://ctos2024.eventscribe.net/fsPopup.asp?PosterID=691386&mode=posterInfo)
46. [Haddox et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS11579)
47. [Heinrich et al. (2024a)](https://www.nature.com/articles/s41591-023-02734-5)
48. [Heinrich et al. (2024b)](https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.TPS766)
49. [Heinrich et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12225728/)
50. [Hirota et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9438854/)
51. [Italiano (2026)](https://pubmed.ncbi.nlm.nih.gov/42690334/)
52. [Khoshnood (2019)](https://pubmed.ncbi.nlm.nih.gov/31068088/)
53. [Liegl et al. (2008)](https://ohsu.elsevierpure.com/en/publications/43c092cb-e799-4ac8-8ebb-5a2479fb7bd5/)
54. [Ma et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4294949/)
55. [Mühlenberg et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095889/)
56. [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bezuclastinib)
57. [National Cancer Institute GIST Treatment PDQ](https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq)
58. [NCCN (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10245542/)
59. [Nemunaitis et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31755321/)
60. [Nilsson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15648083/)
61. [Poole et al. (2015)](https://link.springer.com/article/10.1007/s10120-014-0391-x)
62. [Poort et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27233141/)
63. [SARC (2025)](https://sarctrials.org/sarc044-completes-enrollment/)
64. [Serrano et al. (2023)](https://link.springer.com/article/10.1007/s12094-023-03177-7)
65. [Sonaiya et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11882225/)
66. [Søreide et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26618334/)
67. [Tap et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS11588)
68. [Trent et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.826)
69. [University of California San Diego](https://clinicaltrials.ucsd.edu/trial/NCT05208047)
70. [van de Wal et al. (2022)](https://pure.eur.nl/en/publications/health-related-quality-of-life-and-side-effects-in-gastrointestin/)
71. [Wagner et al. (2018)](https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.11509)
72. [Wagner et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8267845/)
73. [Wagner et al. (2024a)](https://www.cogentbio.com/wp-content/uploads/ASCO-2024-Peak-Part-1.pdf)
74. [Wagner et al. (2024b)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.11533)
75. [Wagner et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11500)
76. [Westerdijk et al. (2026)](https://link.springer.com/article/10.1007/s12029-026-01417-x)

## Related pages
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations.md)
- [Bezuclastinib: Gastrointestinal stromal tumor](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/executive-summary.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economics.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/prevalence.md)
- [Bezuclastinib in Gastrointestinal stromal tumor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/cost-effectiveness-analyses.md)
